MAPT and Alzheimer disease: The vaccines and immunotherapies that have been pursued thus far for AD have focused on sequestering and clearing the aggregating peptides and proteins involved in the pathogenesis and progression of the disease, the β‐amyloid peptide (Aβ) and tau.